Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma

Blood Adv. 2018 Dec 11;2(23):3479-3482. doi: 10.1182/bloodadvances.2018024364.

Abstract

  1. Anti-CD30 therapy for Hodgkin lymphoma led to transient loss of detectable CD4+ T-cell HIV RNA and a decrease in residual plasma viremia.

  2. Targeting nonviral markers expressed on HIV-1 transcriptionally active cells may lead to reduced measures of HIV-1 persistence.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • Brentuximab Vedotin
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / cytology
  • CD8-Positive T-Lymphocytes / metabolism
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV-1 / genetics*
  • Hodgkin Disease / complications
  • Hodgkin Disease / drug therapy*
  • Humans
  • Immunoconjugates / therapeutic use*
  • Immunophenotyping
  • Ki-1 Antigen / immunology*
  • Male
  • RNA, Viral / blood*

Substances

  • Anti-Retroviral Agents
  • Immunoconjugates
  • Ki-1 Antigen
  • RNA, Viral
  • Brentuximab Vedotin